scholarly journals Utilizing Technology-Enabled Intervention to Improve Blood Glucose Self-Management Outcome in Type 2 Diabetic Patients Initiated on Insulin Therapy: A Retrospective Real-World Study

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jian Lin ◽  
Xia Li ◽  
Shan Jiang ◽  
Xiao Ma ◽  
Yuxin Yang ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glycemic Control ◽  
Insulin Therapy ◽  
Fasting Blood Glucose ◽  
Blood Glucose Control ◽  
Diabetic Patients ◽  
Premixed Insulin ◽  
Type 2 Diabetic Patients ◽  
Self Monitoring

Background. The aim of this study was to assess the benefits of a mobile-enabled app through Lilly Connected Care Program (LCCP) in achieving blood glucose control and adhering to self-monitoring of blood glucose in patients with type 2 diabetes mellitus (T2DM). Methods. This retrospective study included T2DM patients who were initiated on insulin therapy (mostly premixed insulin) after failure to respond to oral antidiabetic drugs. Patients were provided with glucometers enabled with synchronous data transmission to healthcare providers and family members. The primary objective was to assess the benefits of LCCP based on changes in fasting blood glucose (FBG) and postprandial glucose (PPG) levels from baseline to 12 weeks. Paired t-test was used to assess the change in blood glucose (BG) from baseline to week 12. Results. In total, 14,085 T2DM patients were recruited. Compared with baseline, significant reductions in FBG and PPG were evident at week 12 (FBG: -0.39 mmol/L; PPG: −0.79 mmol/L; both P < 0.001 ). Furthermore, at week 12, the proportion of patients attaining a target glucose level of FBG <7.0 mmol/L and PPG <10.0 mmol/L was 25.37% and 59.68%, respectively, with a statistically significant increase compared with that at baseline (6.74% and 45.59%, respectively, both P < 0.001 ). The frequent monitoring of patients could gain a higher target achievement of FBG (28.1% vs 24.2%) and PPG (64.4% vs 55.1%) than the occasional monitoring patients. Additionally, the incidence of hypoglycemia gradually decreased and was significantly lower than the baseline level. Conclusions. In T2DM patients with poor glycemic control, the application of mobile enabled intervention (LCCP) along with insulin significantly reduced the hypoglycemia while improving glycemic control during period of naïve initiating insulin therapy. Additionally, the high frequency of BG self-monitoring was associated with better glycemic control.

Improved Blood Glucose Control by Insulin Therapy in Type 2 Diabetic Patients Has No Effect on Lipoprotein(a) Levels

1993 ◽  
Vol 10 (5) ◽  
pp. 427-430 ◽  
Author(s):  
B.H.R. Wolffenbuttel ◽  
P.B. Leurs ◽  
J.P.J.E. Sels ◽  
G.J.W.M. Rondas-Colbers ◽  
P.P.C.A. Menheere ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Insulin Therapy ◽  
Glucose Control ◽  
Blood Glucose Control ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Lipoprotein A ◽  
Type 2 Diabetic

The Effect of Acarbose on Blood Glucose Profiles of Type 2 Diabetic Patients Receiving Insulin Therapy

1993 ◽  
Vol 10 (4) ◽  
pp. 355-358 ◽  
Author(s):  
N. Hotta ◽  
H. Kakuta ◽  
N. Koh ◽  
F. Sakakibara ◽  
T. Haga ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Insulin Therapy ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucose Profiles ◽  
Type 2 Diabetic

Self-monitoring of blood glucose in overweight type 2 diabetic patients

1994 ◽  
Vol 31 (4) ◽  
pp. 215-219 ◽  
Author(s):  
D. B. Muchmore ◽  
J. Springer ◽  
M. Miller
Keyword(s):  
Blood Glucose ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Self Monitoring ◽  
Type 2 Diabetic

scholarly journals Glycemic Control by Combination Therapy of Sitagliptin-Metformin Versus Metformin Alone

KYAMC Journal ◽  
2020 ◽  
Vol 11 (3) ◽  
pp. 150-153
Author(s):  
Misu Rani Saha ◽  
Shahin Ara ◽  
AKM Shahidur Rahman ◽  
Shakilur Rahman ◽  
M Iqbal Hossain ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Blood Sugar ◽  
Combined Therapy ◽  
Fasting Blood Glucose ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Mortality And Morbidity ◽  
Metformin Therapy ◽  
Uncontrolled Diabetes

Background: Type 2 diabetes is a chronic disease characterized by various metabolic defects. Uncontrolled diabetes mellitus gives rise to a number of life-threatening complications that can increase mortality and morbidity. Objectives: This study was carried out to compare the effectiveness of glycemic control between combined therapy of sitagliptin-metformin and metformin monotherapy. Materials and Methods: Total data of 40 newly diagnosed type-2 diabetic patients were compiled in the study. Those patients having HbA1c more than 6% were considered as uncontrolled diabetes. The total subjects were randomly divided into two experimental groups, treated by metformin alone and treated by sitagliptin-metformin combination. Both groups were treated for three consecutive months and they were followed up after 12 weeks of treatment. Fasting blood sugar (FBS), blood sugar 2 hours after breakfast (2-ABF) and glycated hemoglobin A1c(HbA1c) were estimated in both experimental groups before starting of treatment and after 12 weeks of treatment. Results: HbA1c change from baseline was 0.82% with metformin and 1.83% with sitagliptin-metformin combination. Fasting blood glucose changed from 9.41±1.34mmol/l to 8.04±1.10mmol/l with metformin and from 9.75±1.40mmol to 7.25±0.80 with sitagliptin-metformin therapy. Blood sugar 2hours after breakfast changed from 12.68±1.07mmol/l to 10.34±1.68mmol/l with metformin and from 12.65±1.90mmol to 8.74±0.68 with sitagliptin-metformin therapy. The results showed that though both experimental groups reduced FBS, blood sugar 2-ABF, HbA1c at an acceptable level the combined therapy was found to be superior in terms of effectiveness. Conclusion: The administration of sitagliptin-metformin combined therapy to control hyperglycemia uniquely is preferable. KYAMC Journal Vol. 11, No.-3, October 2020, Page 150-153

Effects of Concomitant Administration of Sodium Glucose Co-transporter 2 Inhibitor with Insulin on Hemoglobin A1c, Body Mass Index and Serum Lipid Profile in Japanese Type 2 Diabetic Patients

Drug Research ◽  
2018 ◽  
Vol 68 (12) ◽  
pp. 669-672
Author(s):  
Masataka Kusunoki ◽  
Yukie Natsume ◽  
Tetsuro Miyata ◽  
Kazuhiko Tsutsumi ◽  
Yoshiharu Oshida
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Hemoglobin A1c ◽  
Blood Glucose Control ◽  
Sglt2 Inhibitor ◽  
Serum Triglyceride ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

AbstractIn patients with type 2 diabetes mellitus who show suboptimal blood glucose control under insulin therapy alone, concomitant treatment with an additional hypoglycemic agent that differs in its mechanism of action from insulin may be considered. We conducted this clinical trial to explore whether further control of increased blood glucose level can be achieved with concomitant use of sodium glucose co-transporter 2 (SGLT2) inhibitor as concomitant with other hypoglycemic therapy, as compared to SGLT2 inhibitor monotherapy, in patients with type 2 diabetes mellitus showing decrease in blood glucose level but less than the effect of insulin monotherapy and there was no significant differences. In the SGLT2 inhibitor monotherapy group, decreases of the serum hemoglobin A1c (HbA1c) level, body weight, body mass index (BMI) and serum triglyceride, and elevation of the serum high density lipoprotein cholesterol concentration were observed as compared to the baseline values. In the type 2 diabetic patients under insulin therapy who received combined insulin plus SGLT2 inhibitor therapy, however decreases in the body weight and BMI, with only a tendency towards decrease of the serum HbA1c value, not reaching statistical significance, were observed. The combined therapy group also showed no appreciable changes of the serum triglyceride level, while the serum adiponectin level increased. The present study data indicate that combined insulin plus SGLT2 inhibitor treatment failed to afford any further improvement of the blood glucose control, as compared to SGLT2 monotherapy, in Japanese type 2 diabetic patients.

scholarly journals The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients

2021 ◽  
Vol 37 (7) ◽  
Author(s):  
Cengiz Karacaer ◽  
Taner Demirci ◽  
Hasret Cengiz ◽  
Ceyhun Varim ◽  
Ali Tamer
Keyword(s):  
Glycemic Control ◽  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Objectives: We aimed to determine the effect of short-term intensive insulin therapy (SIIT) on long-term glycemic control in newly-diagnosed Type-2 diabetes mellitus (nT2DM) patients. Methods: In this retrospectively study conducted at Sakarya University Medical Faculty Training and Research Hospital Outpatient Clinic between 2016 and 2019, 65 nT2DM patients were enrolled soon after their SIIT was initiated and were followed for at least a year. Intensive insulin treatment was discontinued after three or 12 months in a total of 65 (23–73-year-old) patients who had been newly diagnosed with T2DM. Intensive insulin therapy was discontinued when glycemic control and the target Glycated Hemoglobin (HbA1c) level had been attained, after which oral anti-diabetic drug (OAD), long-term insulin, and diet therapies were pursued. Results: There was a significant decrease in mean HbA1c from 11.25±1.96% to 6.67±1.07%. Fasting plasma glucose (FPG) was found to be an independent predictor of whether intensive insulin therapy could be discontinued after three months in a model that included FPG, HbA1c, and body mass index measured at baseline. Patients with FPG >13.8 mmol/L were 7.6 times more likely to require intensive insulin therapy beyond three months. There were significant decreases in HbA1c and low-density lipoprotein-cholesterol concentration, but no change in C-peptide between baseline and 3 months of therapy. Conclusion: These results demonstrate that in nT2DM patients, intensive insulin therapy could be effective on long-term glycemic control and high FPG prior to three months of SIIT may predict poor long-term glycemic control. doi: https://doi.org/10.12669/pjms.37.7.4013 How to cite this:Karacaer C, Demirci T, Cengiz H, Varim C, Tamer A. The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients. Pak J Med Sci. 2021;37(7):---------. doi: https://doi.org/10.12669/pjms.37.7.4013 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sign in / Sign up

Export Citation Format

Share Document